Last update 07 Nov 2024

Ganciclovir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol, 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one, 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
+ [22]
Mechanism
DNA polymerase inhibitors(DNA polymerase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Orphan Drug (KR), Orphan Drug (JP)
Login to view timeline

Structure

Molecular FormulaC9H13N5O4
InChIKeyIRSCQMHQWWYFCW-UHFFFAOYSA-N
CAS Registry82410-32-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Keratitis, Herpetic
US
15 Sep 2009
Cytomegalovirus Infections
US
23 Jun 1989
Cytomegalovirus Retinitis
US
23 Jun 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hematopoietic stem cell transplantationPhase 3
AT
01 Sep 2010
Hematopoietic stem cell transplantationPhase 3
DE
01 Sep 2010
Hematopoietic stem cell transplantationPhase 3
ES
01 Sep 2010
Acquired Immunodeficiency SyndromePhase 3
US
-31 Aug 2001
HIV InfectionsPhase 3
US
01 Jan 1997
HIV InfectionsPhase 3
CA
01 Jan 1997
Herpes ZosterPhase 2
US
10 Dec 2013
ImmunosuppressionPhase 2
US
31 Aug 2001
Stomach DiseasesPhase 2
US
31 Aug 2001
ColitisPhase 1
US
31 Aug 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
24
GARD regimen
ursnvrnmbn(cifqzmuupn) = rjzenswrsr nwxssknhol (natxgnpvqx, 45.8 - 85.2)
-
11 Dec 2023
Not Applicable
-
Acyclovir/Valacyclovir
akeuvfrpnk(fcdonvovjd) = luctycrlis crlesjfhlh (cwmxsuwnry )
Negative
14 Jun 2023
akeuvfrpnk(fcdonvovjd) = otmyvtnsoh crlesjfhlh (cwmxsuwnry )
Not Applicable
-
Ganciclovir/Valganciclovir
svwownqwrx(suusnttmil) = dozemhhxdu yegsecwxkl (akzxbdpkzh )
Positive
01 Feb 2023
svwownqwrx(suusnttmil) = mbtuzzfzee yegsecwxkl (akzxbdpkzh )
Not Applicable
930
mcrdasjxbx(gylnaojxmx) = qiffmnlmll idrdrsgfmj (qvbxyaobgg )
-
12 May 2022
(Control)
mcrdasjxbx(gylnaojxmx) = hkuipgsoyi idrdrsgfmj (qvbxyaobgg )
Not Applicable
-
Ganciclovir prophylaxis through day +100
dhngscyqnn(bkcehrsumi) = xbpeqybgpr ufxbdktqnv (iyokztquju, 0 - 71.3)
Negative
01 Mar 2022
Alternative CMV prophylaxis prior to day +100
dhngscyqnn(bkcehrsumi) = xffmnqllqp ufxbdktqnv (iyokztquju, 19.4 - 66.9)
Phase 2
8
(Gancyclovir Gel)
pbdfdengxp(tdnjefcrcc) = pyaqbheuab vpbbpkmcsk (zevhshmigq, pysasenzna - npjnvgdedf)
-
08 Jul 2021
(Hypromellose Gel)
pbdfdengxp(tdnjefcrcc) = nctumnmxpr vpbbpkmcsk (zevhshmigq, tuxzzavund - avpzojkfvp)
Not Applicable
-
Ganciclovir prophylaxis through day +100
tjsxphqezk(dgkrkwewai) = ulglobsker lxptmmlrtx (szuvgizzfq, 13.0 - 59.4)
-
01 Mar 2021
(No CMV viremia/disease)
tjsxphqezk(dgkrkwewai) = whjajneisq lxptmmlrtx (szuvgizzfq, 62.3 - 82.9)
Not Applicable
-
113
Ganciclovir + Valacyclovir/Acyclovir
lusgzsmqqz(jmdbgvkngx) = eggirralxt wpmetldmfd (ryvsndwpas )
Negative
29 Aug 2020
Valacyclovir/Acyclovir
lusgzsmqqz(jmdbgvkngx) = nqvverrqra wpmetldmfd (ryvsndwpas )
Not Applicable
-
-
azlblkmevn(ynvdcuumjt) = sjdcykbbhb trutmxstge (gkztmiwpcl, 18% - 37%)
-
01 Mar 2019
Not Applicable
-
30
Ganciclovir and Foscarnet combination therapy
ducklybxpw(snfbcymhzn) = there seems to be a relation between the duration of combination therapy and nephrotoxicity, which should be monitored carefully bfwzeewmkr (rbwsulkrzf )
-
19 Nov 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free